#Italy #European Market #Rome #biomedical innovation #Haier Biomedical

Haier Biomedical's European Partner Summit in Rome

Haier Biomedical recently held its European Partner Summit in the vibrant city of Rome, focusing on the theme "Advancing Together - Sharing the Future of Biomedical Innovation." This pivotal event attracted 37 partners and key industry figures from 23 European nations, united by a shared vision for the future of biomedicine in Europe. The summit showcased Haier Biomedical's ongoing commitment to the region while unveiling an expanded laboratory solutions portfolio.

A Strategic Shift in Focus

At the summit, Enrique Wang, the Global Market Director, emphasized the company's ambitious goal to derive more than 50% of its global revenue from international markets by 2027. He underscored the significance of Europe in Haier Biomedical's globalization strategy, adhering to the “In Europe, for Europe” principle. This approach emphasizes the delivery of tailored products and services that conform to regional regulatory standards and meet local customer needs.

Semir Selimovic, the Director for North and Central Eastern Europe, discussed the ongoing investments aimed at enhancing local sales, service, and product expertise. Such efforts are designed to ensure greater responsiveness to market requirements, thereby enabling Haier Biomedical to strengthen its presence in one of its fastest-growing international regions.

Innovations to Empower Biomedical Facilities

The summit highlighted several new products, notably the Plasma Apheresis System XJ-III, which recently achieved EU MDR certification. This milestone underlines Haier Biomedical’s dedication to fulfilling Europe’s stringent regulatory requirements concerning blood and plasma technologies. The increasing adoption of CO₂ incubators, centrifuges, biosafety cabinets, and cold storage solutions across Europe reflects the company’s commitment to energy-efficient technologies while adhering to certification standards.

Notably, the launch of comprehensive solutions indicates a significant transition for laboratories, hospitals, and life science entities, aiming to deliver end-to-end solutions.

Automation and Operational Efficiency

Daniele Pericolini, the European Automation Solution Specialist, featured prominently during the summit, outlining strategies focused on leveraging laboratory automation and intelligent blood management. Haier Biomedical is investing in automated biobank solutions that incorporate RFID technology for ultra-low temperature storage and modular automation platforms designed for enhanced sample traceability.

In addressing pressing challenges such as maintaining sample integrity and ensuring efficient temperature monitoring, the company is strategically positioned to meet the increasing demand for advanced biobanking infrastructures in Europe.

Additionally, the U-Blood intelligent blood management system marks a transformative approach from traditional cold storage methods to real-time management of the blood supply chain. This initiative aligns with Europe’s pressing objectives of safety, digitization, and sustainability within healthcare operations.

European Collaborations and Achievements

The summit provided a platform for success stories from various European partners, showcasing localized adaptations of Haier Biomedical’s solutions. For instance, a French partner highlighted the successful deployment of a biosafety cabinet tailored to meet local standards, while a Danish ally shared insights into the successful public tender acquisitions of their ultra-low temperature freezer.

Moreover, the partnership with a Spanish pharmaceutical company underscored the company's ability to manage complex projects across multiple units. The emphasis on reliability, regulatory compliance, and robust after-sales support were identified as pivotal advantages that set Haier Biomedical apart in the competitive landscape.

Financial Growth and Future Aspirations

Haier Biomedical’s expansion and solid financial performance were noteworthy, as the company reported over RMB 2.3 billion in revenue for 2025, with international earnings reaching RMB 840 million, marking over 36% of total revenue. The European region alone saw double-digit growth, significantly contributing to the company’s overall international revenue uplift.

The introduction of AI-driven and automated solutions contributed approximately 15% to the total revenue, indicating a noteworthy technological transformation.

As the summit drew to a close, Haier Biomedical affirmed its determination to strengthen its localized operations and expand its life science solutions while fostering collaborative growth with regional partners. With a blend of global innovation and local execution, the company aspires to solidify its status as a reliable provider of life science solutions throughout Europe in 2026 and beyond.

For more information,visit Haier Biomedical.